Optune Lua uses tumor-treating fields (TTFields) to exert physical forces on the electrically charged components of dividing cancer cells. This results in cell death.

The FDA approved the device for concurrent use with PD-1/PD-L1 inhibitors or docetaxel to treat mNSCLC patients who have progressed on or after a platinum-based regimen.